Carna Biosciences (TSE:4572) Cash-to-Debt : 26.68 (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Carna Biosciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 26.68.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Carna Biosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Carna Biosciences's Cash-to-Debt or its related term are showing as below:

TSE:4572' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.53 Med: 7.34 Max: 26.68
Current: 26.68

During the past 13 years, Carna Biosciences's highest Cash to Debt Ratio was 26.68. The lowest was 1.53. And the median was 7.34.

TSE:4572's Cash-to-Debt is ranked better than
66.11% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs TSE:4572: 26.68

Carna Biosciences Cash-to-Debt Historical Data

The historical data trend for Carna Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Carna Biosciences Cash-to-Debt Chart

Carna Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.74

10.00

7.07

11.25

15.79

Carna Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															15.92	16.28	19.01	15.79	26.68

Competitive Comparison of Carna Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Carna Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carna Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Cash-to-Debt falls into.

Carna Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Carna Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2889.101	/	(126.569	+	56.402)
	=	15.79

Carna Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3159.233	/	(95.001	+	23.404)
	=	26.68

Carna Biosciences (TSE:4572) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Carna Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Carna Biosciences (TSE:4572) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047

Website

http://www.carnabio.com

Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences (TSE:4572) Headlines

No Headlines